5, 1% af de patienter, som fik behandling med BYETTA i de kontrollerede langtidsforsøg (16 uger eller længere).
Injection site reactions Injection site reactions have been reported in approximately 5.1% of subjects receiving BYETTA in long-term (16 weeks or longer) controlled trials.